CALIXAR team will be present at the online BioFIT event, from December 07 to 09, 2021 to discuss about commercial and scientific opportunities linked to our activities.CALIXAR is a biotech company specialized in the identification and isolation of functional membrane therapeutic targets and antigens (GPCRs, Ion channels, Transporters, …). The company is currently investing in the extension of its pipeline of highly druggable membrane protein targets and native antigens. Within the next few years, CALIXAR will be able to offer to pharmaceutical companies native and functional therapeutic targets validated and in a ready-to-discovery format.CALIXAR wants to become a leader in the early discovery segment of drug development based on complex therapeutic targets (membrane proteins), a market predicted to be worth € 70 bn by 2025.About BioFIT:With the highest attending rate of academics, TTOs and research institutions, BioFIT is the place where academia-industry collaborations get started. BioFIT has taken on a whole new dimension becoming the meeting point in Europe for tech transfer and for sourcing early-stage innovations stemming from public research institutions, academic spin-offs, and emerging biotech companies. Together with big pharma, biotech, and diagnostic companies, BioFIT operates as a platform to build partnerships for all public and private actors. BioFIT is also the European marketplace for pre-seed, seed, and Series A investment in Life Sciences.For more information and meet us: BioFIT
